Universal Beteiligungs und Servicegesellschaft mbH Takes $392,000 Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 15,786 shares of Pacira BioSciences, Inc. for approximately $392,000 in the first quarter, reflecting a growing interest from institutional investors in the company.
• Pacira BioSciences' stock has seen a 4.6% increase and currently has a market cap of $1.02 billion, with shares trading around $22.07.
• Recent analyst reports have upgraded Pacira BioSciences, with a consensus rating of "Moderate Buy" and a price target of $25.75, indicating expectations for future growth.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 15,786 shares of the company's stock, valued at approximately $392,000.

A number of other large investors also recently modified their holdings of the business. Easterly Investment Partners LLC raised its position in Pacira BioSciences by 6.2% during the first quarter. Easterly Investment Partners LLC now owns 112,171 shares of the company's stock valued at $2,787,000 after purchasing an additional 6,520 shares in the last quarter. Victory Capital Management Inc. raised its position in Pacira BioSciences by 119.1% during the first quarter. Victory Capital Management Inc. now owns 207,555 shares of the company's stock valued at $5,158,000 after purchasing an additional 112,805 shares in the last quarter. New York State Common Retirement Fund raised its position in Pacira BioSciences by 9.9% during the first quarter. New York State Common Retirement Fund now owns 76,133 shares of the company's stock valued at $1,892,000 after purchasing an additional 6,841 shares in the last quarter. Principal Financial Group Inc. raised its position in Pacira BioSciences by 3.7% during the first quarter. Principal Financial Group Inc. now owns 267,276 shares of the company's stock valued at $6,642,000 after purchasing an additional 9,543 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in Pacira BioSciences during the first quarter valued at approximately $277,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Price Performance

Shares of PCRX stock traded up $1.40 on Thursday, hitting $23.80. 550,783 shares of the stock traded hands, compared to its average volume of 805,851. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -8.58 and a beta of 0.48. The firm has a 50 day simple moving average of $23.64 and a two-hundred day simple moving average of $24.56. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $27.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.01. The firm had revenue of $181.10 million during the quarter, compared to analysts' expectations of $183.11 million. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.22%. The firm's revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.96 EPS. As a group, equities research analysts predict that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Insider Transactions at Pacira BioSciences

In other news, SVP Lauren Riker sold 5,578 shares of the company's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total value of $146,199.38. Following the sale, the senior vice president directly owned 59,564 shares of the company's stock, valued at $1,561,172.44. This represents a 8.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.40% of the company's stock.

Analyst Ratings Changes

A number of research firms have weighed in on PCRX. Needham & Company LLC decreased their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Finally, Truist Financial raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 target price on the stock in a research note on Friday, July 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $25.75.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.